RSV Market: An Unmet Clinical Need For ReViral, And Big Pharma Too

 
• By John Davis

The market landscape for drugs against respiratory syncytial virus infections, an important risk factor in premature infants and the immunocompromised, may change drastically in the future with numerous potential therapies in the pipeline.

Viral infection
• Source: Shutterstock

More from Clinical Trials

More from R&D